Jeffrey T. Jensen

Jeffrey Jensen's clinical experience in family planning inspires his dedication to the development of new methods of contraception. He and his staff focus on translational research designed to bring the advances of the lab into clinical practice. Building on research in rodents, Jensen's group has documented that the phosphodiesterase (PDE) 3 inhibitor, ORG 9935, can prevent maturation of the oocyte both in the culture dish and during stimulated ovarian cycles, and can act as a contraceptive in breeding groups of macaques. It has the advantage of being a nonhormonal strategy that does not affect menstrual cycles. Future experiments in monkeys are needed to determine if the approach is feasible in women. Additional studies with novel inhibitors of oocyte maturation are in progress in the lab as part of the NICHD Contraceptive Research Development Center at ONPRC. Dr Jensen is a Co-Principal Investigator of this grant that is investigating the biology of several highly specific and novel contraceptive strategies, and testing promising applications in the breeding groups.

Globally, surgical sterilization is the most common and effective method of birth control. Because access to this important method is limited by its high cost, the scarcity of providers, and certain surgical risks, particularly in lesser-developed nations, there is a need for a non-surgical method of permanent contraception. Although a number of agents have been evaluated for that role, no approach has gained regulatory approval. Dr. Jensen has investigated Polidocanol, a synthetic, long-chain, fatty alcohol used as a schlerosing agent, for its potential in non-surgical permanent contraception using the nonhuman primate model. The Oregon Permanent Contraception Research Center (OPERM), funded by the Bill and Melinda Gates Foundation, was established at ONPRC to continue the development of polidocanol foam and evaluate other new leads for low cost nonsurgical permanent contraception.


Jeffrey T. Jensen is a Senior Scientist in the Division of Reproductive & Developmental Sciences, Leon Speroff Professor and Vice Chair for Research, Department of Obstetrics & Gynecology in the School of Medicine, OHSU, and Director of the Women's Health Research Unit of the Center for Women's Health at OHSU. He completed medical school at Emory University (1984), an internship at Santa Clara Valley Medical Center (1985), and residency training in Obstetrics and Gynecology at OHSU (1988) before entering active duty military service in the United States Navy. He became a member of the OHSU faculty in 1992. Jensen received a Master of Public Health degree from the University of Washington in 1997, and he joined the ONPRC staff in 1999 as a Women's Reproductive Health Research Fellow.

Key Publications

Jensen, JT, Hanna C, Yao S, et al. Blockade of tubal patency following transcervical administration of polidocanol foam: initial studies in rhesus macaques. Contraception. Epub 2013.

Jensen, JT. Vaginal ring delivery of selective progesterone receptor modulators for contraception. Contraception, 87:314-8, 2013.

Jensen J, Mansour D, Lukkari-Lax E, Inki P, Burock K, Fraser IS. Bleeding patterns with the levonorgestrel-releasing intrauterine system when used for heavy menstrual bleeding in women without structural pelvic pathology: a pooled analysis of randomized controlled studies. Contraception 87:107-12, 2013.

Hanna CB, Yao S, Hennebold JD, Jensen JT. A specific phosphodiesterase (PDE)9 inhibitor promotes in vitro maturation, fertilization and cleavage in Rhesus macaque oocytes. Fertility and Sterility 100:S55, 2013.

Edelman AB, Jensen JT, Doom C, Hennebold JD. Impact of the prostaglandin synthase-2 inhibitor celecoxib on ovulation and luteal events in women. Contraception 87:352-7, 2013.

Edelman AB, Cherala G, Munar MY, et al. Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. Contraception 87:220-6, 2013

Renner RM, Nichols MD, Jensen JT, Li H, Edelman AB. Paracervical block for pain control in first-trimester surgical abortion: a randomized controlled trial. Obstetrics and gynecology 119:1030-7, 2012.

Kaneshiro B, Edelman A, Carlson NE, Nichols M, Jensen J. Unscheduled bleeding with continuous oral contraceptive pills: a comparison of progestin dose. Contraception 86:22-7, 2012.

Kaneshiro B, Edelman A, Carlson NE, Nichols M, Forbes MM, Jensen J. A randomized controlled trial of subantimicrobial-dose doxycycline to prevent unscheduled bleeding with continuous oral contraceptive pill use. Contraception 85:351-8, 2012.

Jensen JT, Garie SG, Trummer D, Elliesen J. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study. Contraception 86:110-8, 2012

Hanna CB, Yao S, Wu X, Jensen JT. Identification of phosphodiesterase 9A as a cyclic guanosine monophosphate-specific phosphodiesterase in germinal vesicle oocytes: a proposed role in the resumption of meiosis. Fertility and sterility 98:487-95 e1, 2012

Edelman AB, Jensen JT, Doom C, Hennebold JD. Impact of the prostaglandin synthase-2 inhibitor celecoxib on ovulation and luteal events in women. Contraception 2012.

Jensen JT, Stouffer RL, Stanley JE, Zelinski MB. Evaluation of the phosphodiesterase 3 inhibitor ORG 9935 as a contraceptive in female macaques: initial trials. Contraception 81:165-71, 2010.


See a full listing of Dr. Jensen's publications